)
Company Research3 May 2024
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
BioNTech (BNTX) investor relations material
BioNTech R&D Day summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.R&D Day summary11 Nov, 2025
Pipeline overview and program updates
Over 20 ongoing Phase II and III oncology trials, with 30+ novel combination cohorts, focusing on immunomodulators, ADCs, and mRNA cancer vaccines across multiple tumor types.
The pipeline includes assets like pumitamig, gotistobart, and individualized neoantigen-specific therapies, spanning solid tumors, breast, lung, GI, GU, and gynecologic cancers.
Strategic pivot back to oncology post-pandemic, with a shift to later-stage, de-risked programs and a disease area-specific approach planned for 2026.
Three-wave clinical strategy: foundational registration trials, expansion into additional indications, and novel combination regimens.
Key partnerships with BMS, DualityBio, MediLink, Genentech, and OncoC4 support pipeline breadth and depth.
Clinical trial data and development milestones
Phase III and registrational trials ongoing in NSCLC, SCLC, TNBC, CRC, gastric, and endometrial cancers, with pivotal data readouts expected in 2025–2026.
Pumitamig, a PD-L1 x VEGF-A bispecific antibody, and gotistobart, an anti-CTLA-4 antibody, are advancing in late-stage trials, showing efficacy across PD-L1 statuses and in combination with chemotherapy and ADCs.
ADCs such as trastuzumab pamirtecan and BNT324/DB-1311 have demonstrated activity in HER2- and B7-H3-expressing tumors, with dose optimization and expansion cohorts underway.
mRNA immunotherapies (FixVac, iNeST) and autogene cevumeran are advancing in adjuvant and metastatic settings, with robust, durable T-cell responses in melanoma, lung, and colorectal cancer.
Mature data in gynecologic and breast cancers support further registrational studies.
R&D strategy and innovation priorities
Emphasis on combination therapies integrating IO, ADCs, and mRNA platforms to address tumor heterogeneity and resistance.
Full AI integration and in-house manufacturing enable rapid, personalized drug development and clinical execution.
Active portfolio management prioritizes high-impact, late-stage programs and efficient resource allocation.
Continued investment in AI-driven drug design, neoantigen prediction, and automated manufacturing.
Ongoing evaluation of novel payloads and immunogenicity enhancements for next-gen ADCs.
Pumitamig: Detail PD-L1 agnostic strategy
ADC pipeline: Prioritized novel targets
mRNA vaccines: Post-melanoma PFS strategy
NSCLC: Which ADC will combine with Pumitamig?
Gotistobart: Path to market beyond squamous NSCLC?
iNeST: How will neoantigen algorithm be optimized?
Promitamyc's unique binding mechanism
Gotistobat's tumor-selective Treg depletion
INEST melanoma trial: key learnings for future
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioNTech earnings date
Q4 202510 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Additionaly its clinical development will target the treatment of infectious diseases, including prophylactic vaccine approach that includes mRNA. It is also developing various neoantigen-based immunotherapies in collaboration with Pfizer Inc.; other checkpoint molecules; and next-generation antigen receptor T-cell products. The company was formerly known as BioNtech Therapeutics GmbH. BioNTech SE was founded in 2008 and is headquartered in Mainz, Germany.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage